

HLA-A*11:01&B2M&KRAS G12V (VGVAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

General Information

Synonyms:	NS3;KI-RAS;RALD;NS;KRAS;K-RAS2A;KRAS2;K-RAS4A;K-RAS2B;C-K-RAS;GTPase Kras;KRAS1;MHC;CFC2;K-RAS4B;RASK2;K-Ras 2
Protein Construction:	Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VGVAVGVGK peptide
Species:	Human
Expression Host:	HEK293 Cells
Accession:	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VGVAVGVGK
Molecular Weight:	258 kDa (Predicted); 260-265 kDa (Non-reducing condition, due to glycosylation)

QC Testing

Biological Activity:	Human HLA-A*11:01&B2M&KRAS G12V (VGVAVGVGK) Tetramer, His-Avi Tag captured on CM5 Chip via Anti-His Antibody can bind HLA-A*11:01&B2M&KRAS G12V (VGVAVGVGK) TCR with an affinity constant of 3.32 μ M as determined in SPR assay (Biacore T200).
Purity:	> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC
Endotoxin:	< 1 EU/ μ g of the protein as determined by the LAL method.
Formulation:	Lyophilized from 0.22 μ m filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μ g/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481